Rani Therapeutics Holdings, Inc. (RANI) vs Zhengye Biotechnology Holding Limited (ZYBT)
A side-by-side comparison of Rani Therapeutics Holdings, Inc. and Zhengye Biotechnology Holding Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RANI
Rani Therapeutics Holdings, Inc.
$0.83HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
ZYBT
Zhengye Biotechnology Holding Limited
$1.13HealthcareDelayed quote: Oct 6, 2026, 3:03 PM EDT
Total return — RANI vs ZYBT
growth of $100 · dividends reinvested · last 2yRANI -45.8% (-26.4%/yr)ZYBT -75.5% (-50.5%/yr)RANI compounded faster over this window
RANI ZYBT
RANI vs ZYBT: by the numbers
- •RANI is the larger company ($54M vs $54M market cap).
- •Both run net losses; ZYBT's is the smaller (-59.97% vs -618.02% net margin).
Metrics side by side
Valuation
| Metric | RANI | ZYBT |
|---|---|---|
| P/S ratio | 11.06 | N/A |
| P/B ratio | 1.37 | 1.50 |
Profitability
| Metric | RANI | ZYBT |
|---|---|---|
| Gross margin | 44.89% | 20.51% |
| Operating margin | -2345.99% | -58.66% |
| Net margin | -618.02% | -59.97% |
| ROE | -76.82% | -27.93% |
| ROIC | -63.96% | -17.88% |
Growth (annualized)
| Metric | RANI | ZYBT |
|---|---|---|
| Revenue CAGR (5Y) | 9.95% | N/A |
| Total return CAGR (5Y) | -46.70% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.